Last reviewed · How we verify

Epidural PCA Ropivacaine

Keimyung University Dongsan Medical Center · Phase 3 active Small molecule

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia.

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia. Used for Epidural anesthesia and analgesia for surgical procedures, Postoperative pain management via patient-controlled epidural analgesia.

At a glance

Generic nameEpidural PCA Ropivacaine
Also known asEpidural patient-controlled analgesia Ropivacaine
SponsorKeimyung University Dongsan Medical Center
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhasePhase 3

Mechanism of action

Ropivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes. When administered via epidural patient-controlled analgesia (PCA), it provides segmental anesthesia and analgesia by blocking sensory and motor nerve conduction in the epidural space. This allows patients to self-administer doses for pain management during and after surgical procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: